What Happened?
New York, NY-based Tonix-Pharmaceuticals Appointed Seth Lederman as Chief Executive Officer, Chairman
About the Company
Tonix Pharmaceuticals develops first-in-class medicines for common disorders of the central nervous system, including fibromyalgia, post-traumatic stress disorder, and episodic tension-type headache. These disorders are characterized by chronic disability, inadequate treatment options, high utilization of healthcare services, and significant economic burden. Tonix`s lead product candidate, TNX-102 SLAttribution (cyclobenzaprine HCl sublingual tablet), is designed to be a fundamental advance in sleep hygiene and pain management for patients suffering from fibromyalgia and post-traumatic stress disorder (PTSD). Product candidate TNX-201Attribution ((R)-isometheptene mucate) is in development for episodic tension-type headache, the most common form of headache.
About the Person
Seth Lederman is Chief Executive Officer, Chairman at Tonix Pharmaceuticals. Previously, Seth held various senior HR leadership roles in the industry.
Info Source
News
Short Profile